NOD2
Nucleotide-binding oligomerization domain-containing protein 2
As of the edition of 20 October 2026, NOD2 (nucleotide-binding oligomerization domain-containing protein 2, UniProt Q9HC29) has 2 drugs tested at it and 4 companies on the list, 2 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9HC29
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Disease areas
- Cancer; Digestive system; Infections; Immune system; Lungs and airways
- Registered trials of its drugs
- 12
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Mifamurtide acid | Marketed | Phase 2 | none listed |
| Inarigivir soproxil | Stopped | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Undetermined | 2 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| invoX Pharma | Route A |
| Gilead Sciences | Route A |
The other 2 companies at NOD2
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at NOD2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.